Intervention 2
Phase 3Small molecule
Intervention 2 is one of 47 small molecule programs targeting Delirium. It is currently in Phase 3.
1
Indications
2
Total Trials
2
Active Trials
46
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
77 competitors in Delirium
#DrugCompanyPhaseTrials
1Exelon
NovartisApproved
Rozerem
TakedaApproved
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Voltaren
NovartisApproved
Aleve
Jazz PharmaceuticalsApproved
Duragesic
CCephalon
Approved
Anerem
AAcacia Pharma Ltd
Approved
Belsomra
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Spravato
WWim Janssens
Approved
Sufenta
LLeaf Vertical Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Intervention 2. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SSultan Qaboos University